Hendrick A, VanVeldhuisen PC, Scott IU, et al. - Researchers retrospectively analyzed data from two randomized clinical trials, to examine the link between intraretinal macular hemorrhage and visual acuity outcomes in eyes with CRVO or HRVO treated with aflibercept, bevacizumab, or observation. Randomization of 362 participants was done in the S tudy of CO mparative Treatments for RE tinal Vein Occlusion 2 and of 88 participants to observation in the S tandard Care versus CO rticosteroid in RE tinal Vein Occlusion Study. Participants were administered monthly intravitreal aflibercept or bevacizumab through Month 6 or observation through Month 8. In 70.7% (116/164) of aflibercept-managed eyes and 63.8% (104/163) of bevacizumab-managed eyes, experts found reduced area of hemorrhage by Month 6, and this was noted in 42.2% (27/64) of observation eyes by Month 8. Overall, visual acuity improvements were reported in relation to improvement in hemorrhage during follow-up, which was also shown to be predictive of visual acuity alterations beyond what was explained by central subfield thickness. As per these data, intraretinal macular hemorrhage represents a crucial indicator of disease severity in retinal vein occlusion.